Fall 2010

Noreen Fraser clearly recalls the day in 2003 when her doctor informed her that the breast cancer she had been diagnosed with 2 years earlier had metastasized to her bones

The management of venous thromboembolism (VTE) disorders is well described in the literature, and comprehensive guidelines are available from the American College of Chest Physicians.

The past 2 to 3 decades saw a palpable therapeutic nihilism associated with the management of patients with advanced renal cell carcinoma (RCC), interrupted briefly by the initial excitement regarding high-dose interleukin-2.

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Cancer-associated thrombosis occurs commonly in patients with cancer, particularly during treatment with anticancer therapies.

Data presented at the recent 35th European Society for Medical Oncology Congress in Milan, Italy, showed a significant survival advantage for men with advanced metastatic castration resistant prostate cancer (CRPC) who received abiraterone acetate compared with placebo.

In recent years, the buzzwords in oncology cancer have been "personalized therapy," in which the entire spectrum of cancer care is customized to the individual patient and his or her cancer.

This month's issue of Contemporary Oncology introduces a new feature called "Perspectives."